Nucleoside News and Research

RSS

Inexpensive generic fixed-dose combined therapies appears the most suitable solution for treating AIDS in developing countries

The development of simple and inexpensive generic fixed-dose combined therapies appears the most suitable solution for making possible this access to treatments in developing countries with meagre resources.

3 Jul 2004

Access to HIV antiretroviral therapies in the developing world should be a major world health priority

One of the strategies adopted consists in utilizing combinations of fixed doses of generic antiretrovirals, involving three medicinal drugs of two different classes in the same tablet.

2 Jul 2004

Schering-Plough submits Japanese application for hepatitis C drug

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's subsidiary in Japan, has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) seeking marketing approval for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection for use in combination with REBETOL(R) (ribavirin) Capsules for the treatment of chronic hepatitis C.

22 Apr 2004

Genetically engineered bugs to fight cancer

GENETICALLY engineered bacteria could become the latest weapons against cancer, Cancer Research UK scientists suggest in a study published today 22nd April 2004.

22 Apr 2004

Oral treatment of chronic hepatitis C

Valeant Pharmaceuticals today presented 24-week data from Phase 2 clinical trials of Viramidine, a nucleoside (guanosine) analog Valeant is developing in oral form for the treatment of chronic hepatitis C (HCV) in conjunction with a pegylated interferon.

17 Apr 2004

IPM takes over Microbicide development to protect against sexual transmission of HIV

International Partnership for Microbicides (IPM) today announced that it has reached a farsighted agreement with Tibotec Pharmaceuticals Ltd, a subsidiary of Johnson & Johnson. The aim is to develop the promising compound TMC120 as a safe and effective microbicide to help protect women from infection with HIV. This agreement marks the first collaboration in the microbicide field between a major healthcare company and a public-private partnership such as IPM.

29 Mar 2004

Cladribine Targeted to Become First Oral Therapy for Multiple Sclerosis

Serono and IVAX Corporation has announced positive results from two clinical trials with a new proprietary oral formulation of cladribine, a potential new treatment for multiple sclerosis (MS). The study results showed that the formulation of oral cladribine which has been developed by Serono and IVAX has met the targets for an orally administered product, with blood levels of cladribine in the expected therapeutic range. Efficacy studies of oral cladribine in MS patients are planned to start late 2004.

23 Mar 2004

Nucleoside News and Research

Inexpensive generic fixed-dose combined therapies appears the most suitable solution for treating AIDS in developing countries

Access to HIV antiretroviral therapies in the developing world should be a major world health priority

Schering-Plough submits Japanese application for hepatitis C drug

Genetically engineered bugs to fight cancer

Oral treatment of chronic hepatitis C

IPM takes over Microbicide development to protect against sexual transmission of HIV

Cladribine Targeted to Become First Oral Therapy for Multiple Sclerosis

One Health, One Mission: The World Organisation for Animal Health on the AMR Frontline

Uniting Against Resistance: The World Health Organization for World Antimicrobial Awareness Week 2023

Tackling Antimicrobial Resistance: A Conversation with Dr. Beverley Isherwood

Latest News